BR112017022779A2 - métodos para detectar uma mutação de deleção em marco (indel) no éxon 9 do gene da calreticulina, para diagnosticar uma doença hematopoiética em um paciente, para determinar a probabilidade de um paciente desenvolver uma mutação em um gene de via jak-stat para determinar o prognóstico de um paciente com uma doença mieloproliferativa, kit, e, sonda ou iniciador oligonucleotídico - Google Patents
métodos para detectar uma mutação de deleção em marco (indel) no éxon 9 do gene da calreticulina, para diagnosticar uma doença hematopoiética em um paciente, para determinar a probabilidade de um paciente desenvolver uma mutação em um gene de via jak-stat para determinar o prognóstico de um paciente com uma doença mieloproliferativa, kit, e, sonda ou iniciador oligonucleotídicoInfo
- Publication number
- BR112017022779A2 BR112017022779A2 BR112017022779-7A BR112017022779A BR112017022779A2 BR 112017022779 A2 BR112017022779 A2 BR 112017022779A2 BR 112017022779 A BR112017022779 A BR 112017022779A BR 112017022779 A2 BR112017022779 A2 BR 112017022779A2
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- mutation
- disease
- methods
- jak
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000035772 mutation Effects 0.000 title abstract 3
- 230000004163 JAK-STAT signaling pathway Effects 0.000 title abstract 2
- 208000014767 Myeloproliferative disease Diseases 0.000 title abstract 2
- 230000037430 deletion Effects 0.000 title abstract 2
- 238000012217 deletion Methods 0.000 title abstract 2
- 238000004393 prognosis Methods 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 108090000549 Calreticulin Proteins 0.000 title 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 title 1
- 208000014951 hematologic disease Diseases 0.000 title 1
- 208000018706 hematopoietic system disease Diseases 0.000 title 1
- 239000002751 oligonucleotide probe Substances 0.000 title 1
- 206010069754 Acquired gene mutation Diseases 0.000 abstract 1
- 101150117824 Calr gene Proteins 0.000 abstract 1
- 210000004602 germ cell Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000037439 somatic mutation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
são providos aqui métodos e composições para a detecção de mutações da linha germinal de deleção no marco no gene calr. também são fornecidos métodos para determinar o prognóstico de doenças mieloproliferativas e a probabilidade de desenvolver mutações somáticas em genes envolvidos na via jak-stat.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562151742P | 2015-04-23 | 2015-04-23 | |
| US62/151742 | 2015-04-23 | ||
| PCT/US2016/028877 WO2016172505A2 (en) | 2015-04-23 | 2016-04-22 | Methods and compositions for the detection of calr mutations in myeloproliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017022779A2 true BR112017022779A2 (pt) | 2018-07-17 |
| BR112017022779B1 BR112017022779B1 (pt) | 2024-04-30 |
Family
ID=57144325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017022779-7A BR112017022779B1 (pt) | 2015-04-23 | 2016-04-22 | Método para detectar uma mutação de deleção in-frame no éxon 9 do gene da calreticulina |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10519509B2 (pt) |
| EP (1) | EP3286336A4 (pt) |
| CN (1) | CN107949643A (pt) |
| BR (1) | BR112017022779B1 (pt) |
| CA (1) | CA2983820A1 (pt) |
| HK (1) | HK1254254A1 (pt) |
| MX (2) | MX2017013623A (pt) |
| WO (1) | WO2016172505A2 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7189399B2 (ja) * | 2017-01-18 | 2022-12-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 骨髄増殖性障害を患う患者の処置のための方法及び医薬組成物 |
| CN107164474B (zh) * | 2017-05-22 | 2020-09-04 | 复旦大学附属华山医院 | 一种检测calr基因2型突变的引物组合物及试剂盒 |
| CN107679366A (zh) * | 2017-08-30 | 2018-02-09 | 武汉古奥基因科技有限公司 | 一种基因组变异数据的计算方法 |
| WO2021039958A1 (ja) * | 2019-08-30 | 2021-03-04 | 東洋鋼鈑株式会社 | 骨髄増殖性腫瘍に関連する遺伝子変異評価用キット |
| CN113764044B (zh) * | 2021-08-31 | 2023-07-21 | 华南理工大学 | 一种构建骨髓增生异常综合征进展基因预测模型的方法 |
| CN115141886B (zh) * | 2022-06-28 | 2023-06-06 | 厦门艾德生物医药科技股份有限公司 | 一种基于高通量测序的髓系白血病基因突变检测的探针引物组及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2877013A1 (fr) | 2004-10-27 | 2006-04-28 | Assist Publ Hopitaux De Paris | Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
| US8841074B2 (en) | 2009-12-04 | 2014-09-23 | Quest Diagnostics Investments Incorporated | MPL mutations in JAK2 V617F negative patients with myeloproliferative disease |
| DK2808338T3 (da) | 2013-09-16 | 2016-06-06 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Mutant calreticulin til diagnose af myeloide maligniteter |
-
2016
- 2016-04-22 WO PCT/US2016/028877 patent/WO2016172505A2/en active Application Filing
- 2016-04-22 CA CA2983820A patent/CA2983820A1/en active Pending
- 2016-04-22 US US15/135,957 patent/US10519509B2/en active Active
- 2016-04-22 BR BR112017022779-7A patent/BR112017022779B1/pt active IP Right Grant
- 2016-04-22 MX MX2017013623A patent/MX2017013623A/es unknown
- 2016-04-22 EP EP16783950.5A patent/EP3286336A4/en not_active Withdrawn
- 2016-04-22 CN CN201680036596.8A patent/CN107949643A/zh active Pending
-
2017
- 2017-10-23 MX MX2022000176A patent/MX2022000176A/es unknown
-
2018
- 2018-10-18 HK HK18113398.1A patent/HK1254254A1/zh unknown
-
2019
- 2019-12-19 US US16/721,038 patent/US20200165688A1/en not_active Abandoned
-
2022
- 2022-02-04 US US17/665,354 patent/US20220364180A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10519509B2 (en) | 2019-12-31 |
| MX2017013623A (es) | 2018-07-06 |
| US20200165688A1 (en) | 2020-05-28 |
| US20160312303A1 (en) | 2016-10-27 |
| WO2016172505A3 (en) | 2016-12-08 |
| BR112017022779B1 (pt) | 2024-04-30 |
| EP3286336A2 (en) | 2018-02-28 |
| WO2016172505A2 (en) | 2016-10-27 |
| EP3286336A4 (en) | 2018-11-14 |
| CA2983820A1 (en) | 2016-10-27 |
| MX2022000176A (es) | 2022-02-21 |
| CN107949643A (zh) | 2018-04-20 |
| HK1254254A1 (zh) | 2019-07-12 |
| US20220364180A1 (en) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017022779A2 (pt) | métodos para detectar uma mutação de deleção em marco (indel) no éxon 9 do gene da calreticulina, para diagnosticar uma doença hematopoiética em um paciente, para determinar a probabilidade de um paciente desenvolver uma mutação em um gene de via jak-stat para determinar o prognóstico de um paciente com uma doença mieloproliferativa, kit, e, sonda ou iniciador oligonucleotídico | |
| Rohde et al. | Recurrent RHOA mutations in pediatric B urkitt lymphoma treated according to the NHL‐BFM protocols | |
| Sáenz-López et al. | VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population | |
| Jiang et al. | Functional polymorphisms in the NBS1 gene and acute lymphoblastic leukemia susceptibility in a Chinese population | |
| Gineau et al. | Balancing immunity and tolerance: genetic footprint of natural selection in the transcriptional regulatory region of HLA-G | |
| Kim et al. | Novel combination markers for predicting survival in patients with muscle invasive bladder cancer: USP18 and DGCR2 | |
| MX2017010122A (es) | Composiciones y metodos para determinar el pronostico de cancer de endometrio. | |
| Cote et al. | Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH) | |
| Hooper et al. | A patient‐derived xenograft model of parameningeal embryonal rhabdomyosarcoma for preclinical studies | |
| Zhao et al. | Interplay between RNA methylation eraser FTO and writer METTL3 in renal clear cell carcinoma patient survival | |
| Pascual et al. | Abstract PS5-02: Assessment of early ctDNA dynamics to predict efficacy of targeted therapies in metastatic breast cancer: Results from plasmaMATCH trial | |
| Yang et al. | TLR9 polymorphisms and systemic lupus erythematosus risk in Asians: a meta-analysis study | |
| MX2017010516A (es) | Biomarcadores para el diagnóstico y pronóstico de trastornos ectáticos de la córnea. | |
| Dai et al. | Host immune gene polymorphisms were associated with the prognosis of non‐small‐cell lung cancer in Chinese | |
| Stegger et al. | Interaction between obesity and the NFKB1-94ins/delATTG promoter polymorphism in relation to incident acute coronary syndrome: A follow up study in three independent cohorts | |
| MX2016012718A (es) | Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina. | |
| CA2842635A1 (en) | Pre-cancerous cells and their identification in the prevention and treatment of cancer | |
| Shu et al. | Possible single-nucleotide polymorphism loci associated with systemic sclerosis susceptibility: a genetic association study in a Chinese Han population | |
| Ferreira et al. | Genetic interactions between chromosomes 11 and 18 contribute to airway hyperresponsiveness in mice | |
| O’Cathail et al. | A metagene of NRF2 expression is a prognostic biomarker in all stage colorectal cancer | |
| Namgoong et al. | No association between CCL2 gene polymorphisms and risk of inflammatory demyelinating diseases in a Korean population | |
| Adams et al. | B21 GENETICS, GENOMICS, AND GENE EXPRESSION IN ASTHMA AND COPD: Genome-Wide Association Study Of Asthma Susceptibility In African American Children And Youth: The Sage Ii Study | |
| cui et al. | Multiomic Screening Unravels the Immunometabolic Signatures and Drug Targets of Age-Related Macular Degeneration | |
| WILSON et al. | Translational Science | |
| Mikacenic et al. | C61 SURVEYING THE LANDSCAPE: OMIC APPROACHES TO STUDY LUNG DISEASE: Common Genetic Polymorphisms In Fas And Mylk Are Highly Associated With Plasma Levels Of Soluble Fas In A Critically Ill Population |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/04/2016, OBSERVADAS AS CONDICOES LEGAIS |